FMC - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 27, 2026

5.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

FMC is undergoing significant restructuring, including a large goodwill impairment and the planned divestiture of its India business, leading to substantial one-time charges and a net loss in 2025.. The company is exploring strategic alternatives, including a potential sale, signaling a period of significant uncertainty and potential transformation.. Significant revenue decline of 18% due to one-time commercial actions in India.

Top Concerns

!Revenue and margins were negatively impacted by the India divestiture actions and ongoing pricing pressures due to competitive dynamics, although underlying cost improvements are noted.
!Forward guidance acknowledges continued pricing pressure but anticipates improved cash flow due to cost reductions and better working capital management.
!Goodwill impairment write-off of $1,356.2 million in 2025, after an annual test in Q3 2025 found no impairment.
!Significant charges ($422 million) and asset impairment ($194.8 million) associated with the India business divestiture, indicating substantial operational issues.
!Competitive Risk due to Patent Expirations (high)

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is balanced with focus on one-time commercial actions in india led to a 23% decrease..

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

5.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

2.0/10

Overall risk profile shows competitive risk due to patent expirations as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

3.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.